Company Name
Changchun BCHT Biotechnology Co.
Year of Establishment
2004
Enterprise Size
more than 1000
Company Introduction
Changchun BCHT Biotechnology Co. is an innovative biopharmaceutical enterprise dedicated to the prevention and treatment of infectious diseases. Since its establishment in 2004, specializing in the R&D, production and sales of human vaccines. At present, BCHT owns three manufacturing sites, covering 225,700 square meters in total, on the basis of core technology R&D and industrialization, BCHT has built stable business model, high market recognition and good social image. The company initially offered to the public and successfully listed on the Science and Technology Innovation Board in June, 2021(BCHT Stock Ticker: 688276).
Quality is the foundation of the company, innovation research is the driving force of BCHT’s development. In 2008, BCHT successfully launched Varicella Vaccine, Live which owned independent intellectual property, its shelf-life up to 36 months which is the longest one in the world, the market share rank first for many years in China. Influenza Vaccine, Live, Nasal, Freeze-dried (launched in 2020), a novel influenza attenuated live vaccine, is a cooperative project with the WHO, which has been included in Global Action Plan for Influenza Vaccine(GAP), it fills the gap in domestic influenza attenuated live vaccines market and has broad market prospects. The Herpes Zoster Vaccine, Live produced by BCHT was approved for marketing in January 2023 which is the world's first Herpes Zoster Vaccine, Live for people aged at or above 40 years old, it fills the gap in domestic herpes zoster vaccines market, providing a new preventive measure for more eligibles.
BCHT—— Devote Biotech Today, Create Health Tomorrow!
Main Competitive Advantages
Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Small Orders Accepted,Reputation,Quality Service,
Website
http://www.bchtpharm.com
Other Competitive Advantages
For the company,many technical person, R&D person and management staff have rich experience in biopharmaceutical line for many years as well as overseas studying and working experince. Meanwhile, BCHT is Focus Support Enterprises by government for the inn
Patents and Copyright
Varicella Vaccine, Live
Milestone
Nov. 2004, SFDA approved the AIDS vaccine to the phase I clinical trial in China.
Aug. 2006, the phase I clinical trial of AIDS vaccine has been finished. Apr. 2007, SFDA approved the AIDS vaccine to the phase II clinical trial in China.
Aug. 2007, Maifeng Biotechnology Co., Ltd., the subsidiary of BCHT, has passed the GMP authentication by SFDA for manufacturing Rabies Vaccine (Vero Cell).
Apr. 2008, BCHT has passed the GMP authentication by SFDA for manufacturing Varicella Vaccine, Live.
2020 BCHT has passed the GMP authentication by SFDA for manufacturing Influenza Vaccine, Live, Nasal, Freeze-dried.
2021 BCHT has successfully listed on SSE.